[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jie Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":114},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643622","investigating-the-efficacy-and-mechanisms-of-individualized-tacs-targeting-anhedonia-in-late-life-depression-100643622",false,"NCT07637773","Investigating the Efficacy and Mechanisms of Individualized tACS Targeting Anhedonia in Late-Life Depression","Efficacy and Mechanisms of Personalized tACS Targeting Anhedonia in Late-Life Depression","Inclusion Criteria:\n\n* (1) Patients were interviewed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Clinical Version (SCID-5-CV) to confirm that they met the DSM-5 diagnostic criteria for \"major depressive disorder\"; (2) Age ≥ 60 years; gender not restricted; (3) Hamilton Depression Scale (HAMD)-17 score \\> 24\n\nExclusion Criteria:\n\n\\- (1) History of severe head trauma or serious neurological conditions such as epilepsy; (2) Any brain devices or implants, including cochlear implants and aneurysm clips; treatments such as transcranial direct current stimulation (tDCS).\n\n(3) Individuals who have undergone other physical modulation therapies within the past 8 weeks, including but not limited to non-convulsive electroconvulsive therapy, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation.","ALL","60 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","This project focuses on clinical translational research into personalized transcranial alternating current stimulation (tACS) for treating anhedonia in late-life depression (LLD). Key components include: (1) Optimizing individualized tACS treatment parameters through randomized, double-blind, controlled trials and establishing precise treatment protocols using deep learning algorithms; (2) Assessing the short-term (2 weeks) and long-term (3 months) efficacy of tACS on depressive symptoms and anhedonia using scales such as the HAMD, SHAPS, and DARS, while monitoring safety; (3) Integrating multimodal detection technologies (64-channel EEG, inflammatory factors\u002Fneurotransmitters, etc.) to elucidate the mechanisms by which tACS alleviates anhedonia through modulating prefrontal neural oscillations (y-band), improving synaptic plasticity (increased BDNF), and regulating neurotransmitters (5-HT, DA). This study will establish, for the first time, an individualized parameter system for tACS treatment of LLD, providing a novel non-pharmacological intervention strategy for clinical practice.",[26,27],"Late-Life Depression","Anhedonia",[29,30,31,32],"transcranial alternating current stimulation","late-life depression","anhedonia","Brain function","RECRUITING","2026-06-09",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2026-03-16",{"date":41,"type":20},"2027-12-31",{"name":43,"class":44},"Jie Li","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100564011","the-impact-of-breathing-training-on-ppsui-a-randomized-controlled-trial-100564011","NCT06623617","The Impact of Breathing Training on PPSUI: A Randomized Controlled Trial","The Effect of Breathing Training on Postpartum Stress Urinary Incontinence : A Randomized Controlled Trial","PPSUI","Inclusion Criteria:\n\n1. Age: ≥18years\n2. 6 weeks to 6 months postpartum\n3. Diagnosed with postpartum stress urinary incontinence (PPSUI) by a pelvic floor rehabilitation specialist\n\nExclusion Criteria:\n\n1. Diabetes mellitus\n2. Body mass index (BMI) \\>30 kg\u002Fm²\n3. Cardiopulmonary or renal dysfunction\n4. Neurological disorders\n5. Pelvic organ prolapse exceeding stage II\n6. History of lumbopelvic surgery\n7. Lumbopelvic pain\n8. Concurrent treatments that may interfere with study outcomes\n9. Professional athletes\n10. Current pregnancy\n\nWithdrawal Criteria:\n\n1. Failure to complete follow-up assessments\n2. Loss of contact with participants\n\nTermination Criteria:\n\n1. Immediate discontinuation if participants experience dizziness, chest tightness, palpitations, or dyspnea during training\n2. Inability to continue intervention due to health issues (e.g., severe complications)\n3. Pregnancy occurring during the intervention period\n4. Non-compliance with prescribed breathing exercises\n5. Participant-initiated withdrawal from the study","FEMALE","18 Years",{"count":57,"type":20},58,[23],"\\*\\*Clinical Trial\\*\\* This clinical trial aims to investigate the clinical therapeutic effects of breathing training on postpartum stress urinary incontinence (PPSUI).\n\nParticipants will:\n\nAll participants will receive standard postpartum care and recovery guidance, including routine examinations, health counseling, basic postpartum recovery recommendations, and educational information.\n\nControl Group: Participants will receive conventional pelvic floor rehabilitation therapy, which may include one or a combination of the following: magnetic stimulation therapy, electromyographic biofeedback therapy, and manual therapy. The specific treatment methods and frequency will be determined based on individual patient conditions.\n\nIntervention Group: In addition to the same pelvic floor rehabilitation therapy as the control group, participants will receive breathing training. Before each session, participants will empty their bladder. The breathing training will be conducted under researcher supervision and guidance, with each session lasting 20 minutes, administered once daily, three times per week for 6 weeks. Participants are encouraged to perform the training in the hospital under researcher supervision. Those unable to attend in-person sessions may conduct home-based training after mastering the technique and must report their training status to researchers afterward. Researchers will monitor weekly training completion and provide timely reminders to ensure adherence. If dizziness or difficulty breathing occurs during training, participants must immediately discontinue the session.",[61],"Stress Urinary Incontinence (SUI)",[63,64],"Postpartum Stress Urinary Incontinence","Breathing training","2026-03-23",{"date":67,"type":37},"2026-03-27",{"date":69,"type":37},"2025-05-01",{"date":71,"type":20},"2026-05-01",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":45},"100579063","the-impact-of-ai-based-fundus-imaging-on-blood-glucose-control-and-fundus-examination-completion-rates-in-outpatient-diabetic-patients-100579063","NCT06819423","The Impact of AI-Based Fundus Imaging on Blood Glucose Control and Fundus Examination Completion Rates in Outpatient Diabetic Patients","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of Type 2 Diabetes Mellitus.\n* Patients with a glycated hemoglobin (HbA1c) level \\> 7%.\n* Ability to comply with all required examinations and provide signed informed consent.\n\nExclusion Criteria:\n\n* No previous diabetic fundus examination.\n* No known diabetic retinopathy.\n* Absence of other ocular diseases that could lead to retinopathy.\n* Subjects from whom clear fundus photographs could not be obtained.\n* Patients with comorbid malignant tumors or severe cardiovascular diseases.\n* Patients anticipated to have difficulties with follow-up or those residing in other provinces.",{"count":80,"type":20},200,[23],"This study aims to evaluate the impact of AI-based fundus imaging on blood glucose control and fundus examination completion rates in diabetic patients by comparing outcomes between those who undergo AI fundus imaging and those who do not. The study is designed as a parallel randomized controlled trial (RCT).\n\nUsing a random number table, 200 diabetic patients visiting the Department of Endocrinology at Sichuan Provincial People's Hospital between December 2024 and December 2025 will be equally divided into two groups: an intervention group and a control group. Each group will consist of 100 patients, assigned unique random numbers. The intervention group will undergo AI-based fundus imaging once, with the imaging process taking approximately 5 minutes. The control group will receive standard eye health education without AI fundus imaging.\n\nThe primary outcomes, including blood glucose control, systemic indicators, and fundus examination completion rates, will be assessed and compared between the two groups at 3-month and 6-month follow-ups. This study seeks to determine the value of AI-based fundus imaging in improving diabetes management and complication prevention in diabetic patients.",[84],"Diabetes","2025-02-10",{"date":87,"type":37},"2025-02-11",{"date":89,"type":37},"2024-12-26",{"date":91,"type":20},"2025-12-26",{"name":43,"class":44},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":45},"100536791","study-of-natural-course-progression-of-diabetic-retinopathy-100536791","NCT06269419","Study of Natural Course Progression of Diabetic Retinopathy","Observational Cohort Study of Natural Course Progression of Diabetic Retinopathy","Inclusion criteria:\n\n* Patients with type 2 diabetes aged 18-75 years\n* Can cooperate with the inspection and sign the informed consent\n* There are no other eye diseases that cause retinal neovascularization\n* There is no known substantial media haze that would hinder fundus image acquisition\n* No history of fundus laser treatment or no possibility of laser treatment expected within six months\n* No previous history of intravitreal drug injection, and no intravitreal drug injection is expected in the next 6 months\n* Macular edema without diabetes (Zeiss OCT women \\\u003C 290µm, male \\\u003C 305µm; OCT female in Heidelberg is \\\u003C 305µm, and for males \\\u003C 320µm)\n* In the field of visual field of clinical mydriasis and Optos photo 7 field of view, DR Lesions were less severe than NPDR\n* No history of eye surgery\n\nExclusion criteria:\n\n* Patients with kidney failure.\n* History of systemic anti-VEGF therapy within the last month.\n* Follow-up is expected to be difficult or patients from other provinces have traction retinal detachment;\n* The patient has a history of allergy","75 Years",{"count":80,"type":20},"OBSERVATIONAL","The goal of this observational study is to observe the formation and development of the non-perfusion area of diabetic retinopathy in the posterior area of the retina in type 2 diabetes patients aged 18-75 years old, who can cooperate with all examinations and sign informed consent, clinical myopathy examination and Optos 7 field of vision with mild than severe NPDR, and no other exclusion indicators.The main questions it aims to answer are whether posterior retinal non-perfusion area occurs earlier than peripheral non-perfusion area and whether the rate of non-perfusion area expansion is a risk factor for the progression of diabetic retinopathy.\n\nParticipants will have protocol-specific follow-up examinations at 1, 2, 3, 4, and 5 years (± 3 months). Additional visits are made as required by the study and the patient's condition.\n\nThe contents of follow-up examinations are:\n\nHistory of other diseases, medications being used, eye diseases, surgeries, treatments, height, weight, and blood pressure.\n\nBest corrected vision, logarithmic visual acuity chart. Tupai OCTA, 24×20mm range, 6×6mm range scan. Optos fundus imaging, color and no red light images. Fundus fluorescence angiography (only preliminary examination for the first time found mild to moderate NPDR patients, who have been angiographed in the past, only at the 5th year, or as required by the condition).\n\nGlycosylated hemoglobin. Creatinine, urea, glomerular filtration rate. Total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol.\n\nUrinary microalbumin\u002Furinary creatinine ACR. Microvisual field.",[105],"Biomarkers of Diabetic Retinopathy","2024-03-11",{"date":108,"type":37},"2024-03-12",{"date":110,"type":37},"2024-02-25",{"date":112,"type":20},"2029-01-01",{"name":43,"class":44},""]